Erste Asset Management GmbH Has $66.43 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Erste Asset Management GmbH reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,009,900 shares of the biopharmaceutical company’s stock after selling 175,000 shares during the period. Agios Pharmaceuticals accounts for approximately 0.8% of Erste Asset Management GmbH’s investment portfolio, making the stock its 28th biggest holding. Erste Asset Management GmbH’s holdings in Agios Pharmaceuticals were worth $66,426,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AGIO. Swiss National Bank grew its stake in shares of Agios Pharmaceuticals by 1.0% in the 4th quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company’s stock valued at $3,311,000 after buying an additional 1,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Agios Pharmaceuticals by 464.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,678 shares of the biopharmaceutical company’s stock valued at $4,130,000 after buying an additional 103,405 shares during the period. AlphaQuest LLC grew its stake in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 2,338 shares during the period. Atria Investments Inc grew its stake in shares of Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 737 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Agios Pharmaceuticals by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 472,547 shares of the biopharmaceutical company’s stock valued at $15,528,000 after buying an additional 6,927 shares during the period.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Stock Down 0.5 %

Agios Pharmaceuticals stock opened at $31.98 on Thursday. Agios Pharmaceuticals, Inc. has a 52 week low of $27.14 and a 52 week high of $62.58. The company’s 50 day moving average price is $33.74 and its two-hundred day moving average price is $42.01. The stock has a market cap of $1.83 billion, a P/E ratio of 2.82 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.